In addition, TGF-β2 mRNA overexpression showed worse PFS than lower levels of TGF-β2 mRNA expression in women with endometrioid ovarian carcinoma (HR, 0.30; 95% CI, 0.12–0.76; P = 0.007) but showed no difference in OS in women with endometrioid ovarian carcinoma women (HR, 0.24; 95% CI, 0.04–1.46; P = 0.093). This evidence concerns the gene TGFB2 and ovarian endometrioid carcinoma.